Compare PSF & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSF | IFRX |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.3M | 225.5M |
| IPO Year | N/A | 2017 |
| Metric | PSF | IFRX |
|---|---|---|
| Price | $17.97 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.29 |
| AVG Volume (30 Days) | 74.0K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.80 | $0.80 |
| 52 Week High | $20.67 | $2.95 |
| Indicator | PSF | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.29 | 27.04 |
| Support Level | $17.81 | $0.81 |
| Resistance Level | $19.48 | $1.07 |
| Average True Range (ATR) | 0.33 | 0.15 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 6.06 | 0.00 |
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.